Centice (Morrisville, NC) developer of a pharmaceutical verification device to improve accuracy of dispensed medications, closed a $6.1M Series C financing. Participants include Fulcrum Financial Group, The Aurora Funds, S-Group Direct Investments, Innovation Ventures and Novak Biddle Venture Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Kerederm (Blacksburg, VA) a development-stage medical device company focused on the use of germicidal phototherapy to prevent and treat skin and nail infections, closed a $2.5M Series A financing. Participants include NewVa Capital Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb.

Metabolon (Durham, NC) a metabolomics services and informatics company focused on detection of small molecule biomarkers, closed a $6M Series C financing, bringing the entire financing round to $12.3M. Participants include Syngenta Ventures, Fletcher Spaght Ventures, Sevin Rosen Funds, Aurora Funds, Harris and Harris Group, Fulcrum Financial Partners and Alexandria Equities.

Micell Technologies (Raleigh, NC) a development-stage medical device company focused on a fluid-based drug eluting stents for the interventional cardiology market, closed a $15M Series B financing. Participants to date have included St.Jude Medical, Invemed Catalyst Fund and GE.

Almeria Sciences (Atlanta, GA) a clinical-stage biopharma company focused on ophthalmic disease and treatment of diabetic macular edema, closed a $5M Series C, bringing the total round to $35. Participants have included Polaris Venture Partners, Intersouth Partners, Venrock Associates, Domain Associates and Scale Venture Partners.

Union Springs Pharmaceuticals (Union, KY) a commercial-stage developer of OTC antiinfective washes for emergency first responders, closed a $5M Series A financing. Participants include Blue Chip Venture Company.

Chimerix (Durham, NC) a clinical-stage developing broad spectrum antiviral agents focusing on CMV and BK viruria, closed a $16M Series E financing. Participants include Canaan Partners, Alta Partners, Sanderling Ventures and Asset Management Company.

CardioMEMS (Atlanta, GA) a commercial-stage medical device company with an approved endovascular abdominal aortic aneurysm pressure management system and clinical-stage wireless sensing device for management of cardiovascular diseases such as aneurysms, heart failure and hypertension, closed a $22.1M Series F financing. Participants may have included Arcapita Ventures, Boston Millennia Partners, Medtronic, Easton Capital Partners, [...]

Liquidia (Morrisville, NC) a development-stage company focused on improving delivery of inhaled therapeutics and vaccines via nanoparticles with optimized characteristics for increased target specificity, closed a $7M Series C financing. Participants include Canaan Partners, Pappas Ventures, New Enterprise Associates and Firelake Capital.

Quantum Immunologics (Tampa, FL) a clinical-stage biopharmaceutical company focused on breast cancer, closed a $2.2M Series A financing. Participants include Mentor Capital.

Medivance (Louisville, KY) a commercial-stage device company focused on non-invasive core temperature management, closed a $8.1M Series E financing. Participants include Quellos Private Capital, MDY Healthcare, Cross Atlantic Partners, Skyline Ventures, Camden Partners, Partisan Management Group, Nikko Synergy Ventures, Kimberly-Clark, CSFB Private Equity and New England Capital Partners.

Viamet Pharmaceuticals (Morrisville, NC) a pre-clinical stage pharmaceutical company focused on small-molecule inhibitors of metalloenzymes, closed a $18M Series B financing. Participants include Novartis Option Fund. Lilly Ventures, Intersouth Partners, Hatteras Venture Partners, Lurie Investment Fund and Astellas Venture Management.

CeNeRx BioPharma (Cary, NC) a clinical-stage biopharmaceutical company focused on diseases of the central nervous system, closed a $4M Series C financing. Participants include Aisling Capital, L Capital Partners and Pappas Ventures.